Table 3

ORs and 95% CIs for ICC HPV-16EP or AA positive according to HLA.

Controls
 AA Cases
 EP Cases

HLA
 C/N
 C/N
 Crude
 Adjusted
 C/N
 Crude
 Adjusted


Controls
 Cases
 OR
 OR (95% CI)
 Cases
 OR
 OR (95% CI)

n = 257
 n = 37

n = 24

DQA1






          *0101/04
 79/178
 5/32
 0.35
 0.34(0.12–0.93)
 9/15
 1.35
 1.31 (0.53–3.25)
          *0102
 80/177
 10/27
 0.82
 0.82(0.37–1.83)
 12/12
 2.21
 2.32 (0.96–5.62)
DQB1






          *0301
 78/179
 9/28
 0.74
 0.74(0.32–1.70)
 8/16
 1.15
 1.08 (0.42–2.75)
     *05
 95/162
 5/32
 0.27
 0.27(0.10–0.75)
 10/14
 1.22
 1.29 (0.53–3.14)
          *0501
 71/186
 4/33
 0.32
 0.30 (0.10–0.92)
 9/15
 1.57
 1.56 (0.63–3.89)
     *06
 87/170
 16/21
 1.49
 1.49 (0.72–3.08)
 12/12
 1.95
 2.02 (0.84–4.88)
          *0602
 44/213
 9/28
 1.56
 1.45 (0.62–3.39)
 8/16
 2.42
 2.13 (0.83–5.50)
DRB1






     *01
 52/205
 4/33
 0.48
 0.45 (0.15–1.37)
 7/17
 1.62
 1.51 (0.57–4.03)
          *0102
 29/228
 1/36
 0.22
 0.18 (0.02–1.44)
 6/18
 2.62
 2.18 (0.75–6.29)
     *04
 74/183
 10/27
 0.92
 0.94 (0.42–2.09)
 3/21
 0.35
 0.34 (0.10–1.21)
     *13
 61/196
 9/28
 1.03
 1.21 (0.52–2.78)
 5/19
 0.85
 1.09 (0.37–3.16)
          *1302
 27/230
 0/37
 0.00
3/21
 1.22
 1.62 (0.42–6.16)
     *15
 34/223
 10/27
 2.43
 2.34 (1.00–5.46)
 8/16
 3.28
 2.99 (1.13–7.86)
          *1503
 14/243
 5/32
 2.71
 2.62 (0.83–8.27)
 4/20
 3.47
 3.75 (0.99–12.42)
DRB1-DQB1 haplotypes






     0102-0501
 29/228
 1/36
 0.22
 0.18 (0.02–1.44)
 6/18
 2.62
 2.18 (0.75–6.29)
     15-0602
 33/224
 8/29
 1.87
 1.84 (0.75–4.53)
 8/16
 3.39
 3.08 (1.17–8.14)
     1503-0602
 14/243
 5/32
 2.71
 2.62 (0.83–8.27)
 4/20
 3.47
 3.50 (0.99–12.42)
     08041-0301
 5/252
 0/27

2/22
 4.58
 3.59 (0.48–27.13)
     09012-0201/02
 3/254
 1/36
 2.35
 2.62 (0.25–27.79)
 1/23
 3.68
 5.00 (0.47–53.36)

de Araujo Souza et al. BMC Cancer 2008 8:246   doi:10.1186/1471-2407-8-246